However, the effects of TKIs on immune function in patients can contribute to hepatitis B reactivation, including episodes of hepatitis associated with elevated alanine aminotransferase (ALT), increased mortality from liver failure, and the progression of chronic myelogenous leukemia after reduction or discontinuation of TKIs. This evidence concerns the gene GPT and Hepatic failure.